Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma: Pre-treatment versus in-therapy results

A. Giostra, E. Richetta, M. Pasquino, A. Miranti, Claudia Cutaia, G. Brusasco, R. E. Pellerito, M. Stasi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Treatment with radioiodine is a standard procedure for patients with well-differentiated thyroid cancer, but the main approach to the therapy is still empiric, consisting of the administration of fixed activities. A predictive individualized dosimetric study may represent an important tool for physicians to determine the best activity to prescribe. The aim of this work is to compare red marrow and blood absorbed dose values obtained in the pre-treatment (PT) dosimetry phase with those obtained in the in-treatment (IT) dosimetry phase in order to estimate the predictive power of PT trial doses and to determine if they can be used as a decision-making tool to safely administer higher 131I activity to potentially increase the efficacy of treatment. The PT and IT dosimetry for 50 patients has been evaluated using three different dosimetric approaches. In all three approaches blood and red marrow doses, are calculated as the sum of two components, the dose from 131I activity in the blood and the dose from 131I activity located in the remainder of the body (i.e. the blood and whole-body contributions to the total dose). PT and IT dose values to blood and red marrow appear to be well correlated irrespective of the dosimetric approach used. Linear regression analyses of PT and IT total doses, for blood and red marrow, and the whole-body contribution to these doses, showed consistent best fit slope and correlation coefficient values of approximately 0.9 and 0.6, respectively: analyses of the blood dose contribution to the total doses also yielded similar values for the best fit slope but with correlation coefficient values of approximately 0.4 reflecting the greater variance in these dose estimates. These findings suggest that pre-treatment red marrow dose assessments may represent an important tool to personalize metastatic thyroid cancer treatment, removing the constraints of a fixed activity approach and permitting potentially more effective higher 131I activities to be safely used in-treatment.

Original languageEnglish
Pages (from-to)4316-4326
Number of pages11
JournalPhysics in Medicine and Biology
Volume61
Issue number11
DOIs
Publication statusPublished - May 20 2016

Fingerprint

Thyroid Neoplasms
Bone Marrow
Therapeutics
Linear Models
Decision Making
Regression Analysis

Keywords

  • blood and red marrow dosimetry
  • I131
  • internal dosimetry

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma : Pre-treatment versus in-therapy results. / Giostra, A.; Richetta, E.; Pasquino, M.; Miranti, A.; Cutaia, Claudia; Brusasco, G.; Pellerito, R. E.; Stasi, M.

In: Physics in Medicine and Biology, Vol. 61, No. 11, 20.05.2016, p. 4316-4326.

Research output: Contribution to journalArticle

Giostra, A. ; Richetta, E. ; Pasquino, M. ; Miranti, A. ; Cutaia, Claudia ; Brusasco, G. ; Pellerito, R. E. ; Stasi, M. / Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma : Pre-treatment versus in-therapy results. In: Physics in Medicine and Biology. 2016 ; Vol. 61, No. 11. pp. 4316-4326.
@article{a3426f0a881440238e595a32f215ce04,
title = "Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma: Pre-treatment versus in-therapy results",
abstract = "Treatment with radioiodine is a standard procedure for patients with well-differentiated thyroid cancer, but the main approach to the therapy is still empiric, consisting of the administration of fixed activities. A predictive individualized dosimetric study may represent an important tool for physicians to determine the best activity to prescribe. The aim of this work is to compare red marrow and blood absorbed dose values obtained in the pre-treatment (PT) dosimetry phase with those obtained in the in-treatment (IT) dosimetry phase in order to estimate the predictive power of PT trial doses and to determine if they can be used as a decision-making tool to safely administer higher 131I activity to potentially increase the efficacy of treatment. The PT and IT dosimetry for 50 patients has been evaluated using three different dosimetric approaches. In all three approaches blood and red marrow doses, are calculated as the sum of two components, the dose from 131I activity in the blood and the dose from 131I activity located in the remainder of the body (i.e. the blood and whole-body contributions to the total dose). PT and IT dose values to blood and red marrow appear to be well correlated irrespective of the dosimetric approach used. Linear regression analyses of PT and IT total doses, for blood and red marrow, and the whole-body contribution to these doses, showed consistent best fit slope and correlation coefficient values of approximately 0.9 and 0.6, respectively: analyses of the blood dose contribution to the total doses also yielded similar values for the best fit slope but with correlation coefficient values of approximately 0.4 reflecting the greater variance in these dose estimates. These findings suggest that pre-treatment red marrow dose assessments may represent an important tool to personalize metastatic thyroid cancer treatment, removing the constraints of a fixed activity approach and permitting potentially more effective higher 131I activities to be safely used in-treatment.",
keywords = "blood and red marrow dosimetry, I131, internal dosimetry",
author = "A. Giostra and E. Richetta and M. Pasquino and A. Miranti and Claudia Cutaia and G. Brusasco and Pellerito, {R. E.} and M. Stasi",
note = "M. Stasi non risulta correttamente affiliato in questa pubblicazione. La posizione di M. Stasi {\`e} regolata da convenzione tra Ospedale Mauriziano, Torino e IRCCS Candiolo",
year = "2016",
month = "5",
day = "20",
doi = "10.1088/0031-9155/61/11/4316",
language = "English",
volume = "61",
pages = "4316--4326",
journal = "Physics in Medicine and Biology",
issn = "0031-9155",
publisher = "IOP Publishing Ltd.",
number = "11",

}

TY - JOUR

T1 - Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma

T2 - Pre-treatment versus in-therapy results

AU - Giostra, A.

AU - Richetta, E.

AU - Pasquino, M.

AU - Miranti, A.

AU - Cutaia, Claudia

AU - Brusasco, G.

AU - Pellerito, R. E.

AU - Stasi, M.

N1 - M. Stasi non risulta correttamente affiliato in questa pubblicazione. La posizione di M. Stasi è regolata da convenzione tra Ospedale Mauriziano, Torino e IRCCS Candiolo

PY - 2016/5/20

Y1 - 2016/5/20

N2 - Treatment with radioiodine is a standard procedure for patients with well-differentiated thyroid cancer, but the main approach to the therapy is still empiric, consisting of the administration of fixed activities. A predictive individualized dosimetric study may represent an important tool for physicians to determine the best activity to prescribe. The aim of this work is to compare red marrow and blood absorbed dose values obtained in the pre-treatment (PT) dosimetry phase with those obtained in the in-treatment (IT) dosimetry phase in order to estimate the predictive power of PT trial doses and to determine if they can be used as a decision-making tool to safely administer higher 131I activity to potentially increase the efficacy of treatment. The PT and IT dosimetry for 50 patients has been evaluated using three different dosimetric approaches. In all three approaches blood and red marrow doses, are calculated as the sum of two components, the dose from 131I activity in the blood and the dose from 131I activity located in the remainder of the body (i.e. the blood and whole-body contributions to the total dose). PT and IT dose values to blood and red marrow appear to be well correlated irrespective of the dosimetric approach used. Linear regression analyses of PT and IT total doses, for blood and red marrow, and the whole-body contribution to these doses, showed consistent best fit slope and correlation coefficient values of approximately 0.9 and 0.6, respectively: analyses of the blood dose contribution to the total doses also yielded similar values for the best fit slope but with correlation coefficient values of approximately 0.4 reflecting the greater variance in these dose estimates. These findings suggest that pre-treatment red marrow dose assessments may represent an important tool to personalize metastatic thyroid cancer treatment, removing the constraints of a fixed activity approach and permitting potentially more effective higher 131I activities to be safely used in-treatment.

AB - Treatment with radioiodine is a standard procedure for patients with well-differentiated thyroid cancer, but the main approach to the therapy is still empiric, consisting of the administration of fixed activities. A predictive individualized dosimetric study may represent an important tool for physicians to determine the best activity to prescribe. The aim of this work is to compare red marrow and blood absorbed dose values obtained in the pre-treatment (PT) dosimetry phase with those obtained in the in-treatment (IT) dosimetry phase in order to estimate the predictive power of PT trial doses and to determine if they can be used as a decision-making tool to safely administer higher 131I activity to potentially increase the efficacy of treatment. The PT and IT dosimetry for 50 patients has been evaluated using three different dosimetric approaches. In all three approaches blood and red marrow doses, are calculated as the sum of two components, the dose from 131I activity in the blood and the dose from 131I activity located in the remainder of the body (i.e. the blood and whole-body contributions to the total dose). PT and IT dose values to blood and red marrow appear to be well correlated irrespective of the dosimetric approach used. Linear regression analyses of PT and IT total doses, for blood and red marrow, and the whole-body contribution to these doses, showed consistent best fit slope and correlation coefficient values of approximately 0.9 and 0.6, respectively: analyses of the blood dose contribution to the total doses also yielded similar values for the best fit slope but with correlation coefficient values of approximately 0.4 reflecting the greater variance in these dose estimates. These findings suggest that pre-treatment red marrow dose assessments may represent an important tool to personalize metastatic thyroid cancer treatment, removing the constraints of a fixed activity approach and permitting potentially more effective higher 131I activities to be safely used in-treatment.

KW - blood and red marrow dosimetry

KW - I131

KW - internal dosimetry

UR - http://www.scopus.com/inward/record.url?scp=84971506942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971506942&partnerID=8YFLogxK

U2 - 10.1088/0031-9155/61/11/4316

DO - 10.1088/0031-9155/61/11/4316

M3 - Article

AN - SCOPUS:84971506942

VL - 61

SP - 4316

EP - 4326

JO - Physics in Medicine and Biology

JF - Physics in Medicine and Biology

SN - 0031-9155

IS - 11

ER -